Enliven Therapeutics Inc. (ELVN)
Healthcare
Biotechnology
54.80 $
+1.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Enliven Therapeutics Inc. (ELVN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -70 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| -8.8 | -8.8 | -22 | -8.5 | -19 | -32 | -61 | -73 | -70 | |
| – | – | 0.0 | 0.0 | 0.1 | 0.2 | 0.3 | 0.3 | 0.3 | |
| – | 0.6 | 0.9 | 0.1 | 1.9 | 3.2 | 13 | 20 | 34 | |
| – | – | – | 9.8 | 1.9 | – | – | – | – | |
| -0.2 | 1.2 | 0.7 | 0.6 | 3.6 | 0.4 | 1.4 | -4.5 | -1.1 | |
| 0.0 | 0.0 | 0.1 | 0.5 | 0.2 | 0.6 | 0.1 | 0.0 | 0.2 | |
| – | – | -24 | -0.5 | -0.2 | -0.6 | -148 | -36 | -174 | |
| – | – | – | – | -0.2 | 0.0 | – | – | 0.6 | |
| 11 | 6.5 | 44 | 131 | -1.0 | -1.8 | 234 | 133 | 219 | |
| 2.2 | -2.3 | -2.4 | 122 | -20 | -34 | 25 | 24 | -25 | |
| -8.8 | -8.8 | -22 | -9.0 | -19 | -33 | -61 | -73 | -70 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.